| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/4/21 A | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +3.25% | +11.75% | +68.51% | +151.55% | 1,224B | |
| -0.21% | +4.34% | +45.60% | +87.22% | 662B | |
| +1.30% | +3.18% | +29.15% | +107.70% | 514B | |
| +0.42% | +3.20% | +54.15% | +67.18% | 388B | |
| +2.42% | +3.35% | +74.00% | +46.21% | 361B | |
| +1.12% | +4.52% | +35.30% | +58.08% | 302B | |
| +6.96% | +8.86% | +11.27% | +36.62% | 271B | |
| +1.23% | +6.17% | +59.71% | +77.19% | 249B | |
| +3.34% | +9.81% | +44.67% | +120.33% | 205B | |
| Average | +2.75% | +2.59% | +46.93% | +83.56% | 464.09B | |
| Weighted average by Cap. | +2.13% | +3.04% | +51.36% | +98.82% |
Employees
2,191
Sector
Pharmaceuticals
